8-K: Apyx Medical Reports Strong Q3 2025, Boosts Full-Year Revenue Outlook

Apyx Medical Corporation announced robust third-quarter 2025 financial results, driven by the successful U.S. launch of its AYON Body Contouring System and an upward revision of its full-year revenue guidance.

Summary

• Total revenue for the third quarter of 2025 increased by 12.1% to $12.9 million, compared to $11.5 million in the prior year period.
• Surgical Aesthetics revenue grew 19.1% to $11.1 million in Q3 2025, with U.S. sales increasing over 30%.
• OEM revenue decreased by 18% to $1.8 million in Q3 2025.
• Net loss attributable to stockholders significantly improved to $2.0 million in Q3 2025, down from $4.7 million in Q3 2024.
• Adjusted EBITDA loss decreased 96% to $0.1 million for Q3 2025, compared to $2.4 million for Q3 2024.
• The full U.S. commercial launch of the AYON Body Contouring System was initiated at the end of Q3 2025, with pre-order demand exceeding expectations.
• A new 510(k) premarket notification was submitted to the FDA in October 2025 for AYON's label expansion to include power liposuction.
• Full-year 2025 total revenue guidance was increased to a range of $50.5 million to $52.5 million, up from the previous guidance of $50.0 million to $52.0 million.
• Surgical Aesthetics revenue guidance for FY2025 was raised to $43.0 million to $45.0 million, while OEM revenue guidance was lowered to approximately $7.5 million.
• Operating expenses for the full year 2025 are expected to be less than $40.0 million.

Sentiment

Score: 8

Explanation: The company demonstrated significant operational improvements, including a substantial reduction in net loss and adjusted EBITDA loss, driven by strong growth in its core Surgical Aesthetics segment. The successful U.S. launch of the AYON Body Contouring System, with demand exceeding expectations, and the strategic move to expand its label to include power liposuction, position the company for continued market penetration and revenue acceleration. The upward revision of full-year revenue guidance further reinforces a positive trajectory.

Positives

• Total revenue increased by 12.1% to $12.9 million in Q3 2025, demonstrating strong growth.
• Surgical Aesthetics revenue, the core business, grew 19.1% to $11.1 million, with U.S. sales up over 30%.
• Net loss attributable to stockholders significantly reduced to $2.0 million from $4.7 million year-over-year, indicating improved profitability.
• Adjusted EBITDA loss decreased by 96% to $0.1 million, reflecting substantial operational efficiency gains.
• The full U.S. commercial launch of the AYON Body Contouring System was successful, with customer demand for pre-orders exceeding expectations.
• Gross profit increased to $8.3 million from $7.0 million, and gross margin improved to 64.4% from 60.5% due to favorable segment and geographic mix.
• Operating expenses decreased by $1.5 million to $9.1 million, driven by reductions in SG&A, R&D, salaries, and professional services.
• Full-year 2025 total revenue guidance was revised upwards to $50.5 million $52.5 million, signaling confidence in future performance.
• Surgical Aesthetics revenue guidance for FY2025 was also increased to $43.0 million $45.0 million.
• Submission of a new 510(k) for AYON label expansion to include power liposuction could significantly enhance the product's market position and utility.

Negatives

• OEM revenue decreased by 18% to $1.8 million in Q3 2025 compared to the prior year.
• OEM revenue guidance for FY2025 was decreased to approximately $7.5 million from $8.0 million.
• Total revenue for the nine months ended September 30, 2025, saw a slight decrease of 0.6% compared to the same period last year.
• International sales decreased by 4.0% in Q3 2025 and 5.7% for the nine months ended September 30, 2025.
• Net loss attributable to stockholders for the nine months ended September 30, 2025, was $9.9 million.
• Cash and cash equivalents decreased to $25.1 million as of September 30, 2025, from $31.7 million at December 31, 2024.
• Total stockholders' equity decreased to $5.8 million as of September 30, 2025, from $14.2 million at December 31, 2024.

Risks

• The Company's ability to gain requisite regulatory approvals for its products from the FDA and other governmental and regulatory bodies, both domestically and internationally, poses a risk.
• Sudden or extreme volatility in commodity prices and availability, including supply chain disruptions, could impact operations.
• Component shortages, manufacturing disruptions, or logistics challenges may affect production and delivery.
• Changes in general economic, business, or demographic conditions or trends could negatively influence demand.
• Changes in and effects of the geopolitical environment may introduce unforeseen challenges.
• Liabilities and costs which the Company may incur from pending or threatened litigations, claims, disputes, or investigations represent a financial and operational risk.

Future Outlook

The company plans to continue accelerating the adoption of AYON and expanding its user base, which is expected to drive single-use handpiece sales growth. Anticipated demand will be further boosted by the pending FDA clearance of the 510(k) premarket notification submitted in October 2025 for AYON's label expansion to include power liposuction. Upon receiving this clearance, the new functionality will be activated in already installed AYON systems. The company has raised its full-year 2025 total revenue guidance to a range of $50.5 million to $52.5 million, with Surgical Aesthetics revenue expected to be $43.0 million to $45.0 million, and operating expenses projected to be less than $40.0 million.

Management Comments

• "While we are still in the early stages of ramping up the broader commercial program, I am excited to announce that we reported a 19% increase in Surgical Aesthetics revenue for the third quarter of 2025." Charlie Goodwin, President and Chief Executive Officer.
• "Looking ahead, we plan to continue accelerating the adoption of AYON and expanding its user base, which will drive single-use handpiece sales growth." Charlie Goodwin.
• "Anticipated demand will be driven, in part, by the pending FDA clearance of the 510(k) premarket notification submitted last month for the label expansion of AYON to include power liposuction." Charlie Goodwin.
• "Upon receiving this market clearance, we will be able to activate this new functionality in AYON systems already installed at surgical centers across the U.S. through the ongoing commercial launch." Charlie Goodwin.

Industry Context

The surgical aesthetics market is characterized by continuous innovation and a strong demand for advanced body contouring solutions. Apyx Medical's AYON system, integrating fat removal, closed-loop contouring, and Renuvion's tissue contraction, positions the company to capitalize on this trend by offering a comprehensive, all-in-one platform. The strategic pursuit of label expansion to include power liposuction aims to further differentiate AYON, potentially establishing it as a 'new gold standard' and streamlining surgical workflows, which could enable the company to gain significant market share against specialized, single-function devices from competitors.

Comparison to Industry Standards

• The filing states AYON is 'the first of its kind' and aims to be the 'new gold standard' in surgical aesthetics, but does not provide specific comparable companies, projects, or results to global benchmarks.

Legal Proceedings

• The filing mentions general risks related to pending or threatened litigations, claims, disputes, or investigations, but does not detail any specific ongoing legal proceedings.

Stakeholder Impact

• Shareholders: Positive impact due to improved financial performance, successful product launch, and increased revenue guidance, potentially leading to increased share value.
• Customers (Surgeons/Clinics): Access to an innovative, all-in-one body contouring system (AYON) with potential for expanded functionality (power liposuction), streamlining workflow and enhancing patient outcomes.
• Employees: Positive outlook due to company growth and product success, potentially leading to job security and opportunities.
• Suppliers: Continued demand for components and materials for AYON and Renuvion products.
• Creditors: Improved financial health and reduced losses may enhance creditworthiness.

Next Steps

• Continue accelerating the adoption of AYON and expanding its user base.
• Drive single-use handpiece sales growth, particularly for AYON.
• Await FDA clearance for the 510(k) label expansion of AYON to include power liposuction.
• Activate new power liposuction functionality in installed AYON systems upon regulatory clearance.
• Host a conference call on November 6, 2025, at 8:00 a.m. ET to discuss Q3 2025 results and host a Q&A session.

Key Dates

Recommendation

The company demonstrated significant operational improvements, including a substantial reduction in net loss and adjusted EBITDA loss, driven by strong growth in its core Surgical Aesthetics segment. The successful U.S. launch of the AYON Body Contouring System, with demand exceeding expectations, and the strategic move to expand its label to include power liposuction, position the company for continued market penetration and revenue acceleration. The upward revision of full-year revenue guidance further reinforces a positive trajectory, suggesting strong future performance and potential for capital appreciation.

Keywords

Apyx Medical, APYX, AYON Body Contouring System, Renuvion, Surgical Aesthetics, Medical Devices, FDA 510(k), Power Liposuction, Financial Results, Q3 2025, Revenue Guidance, Adjusted EBITDA, Cosmetic Surgery